API Gallery
The Betamethasone market is witnessing a CAGR of 5.3% during the forecast period of 2025-2035.
The Ibandronate Sodium market is projected to grow at a CAGR of 5.2% from 2025 to 2035, driven by its critical role in the management of osteoporosis and bone metastases associated with cancer.
The Ibrexafungerp Citrate market is projected to grow at a CAGR of 7.6% from 2025 to 2035, driven by increasing demand for novel antifungal therapies and rising rates of fungal infections, including drug-resistant strains.
The Ibrutinib market is projected to grow at a CAGR of 6.8% from 2025 to 2035, driven by increasing global incidence of B-cell malignancies and the expanding adoption of targeted cancer therapies.
The Ibuprofen Lysinate market is projected to grow at a CAGR of 5.1% from 2025 to 2035, driven by its enhanced absorption profile, faster onset of action, and growing preference in acute pain management and anti-inflammatory therapies.
The Ibuprofen market is projected to grow at a CAGR of 4.7% from 2025 to 2035, driven by its widespread use as an over-the-counter (OTC) nonsteroidal anti-inflammatory drug (NSAID) for pain relief, fever reduction, and inflammation management.
The Ibuprofen Piconol market is projected to grow at a CAGR of 4.6% from 2025 to 2035, driven by its application in treating pain and inflammation with improved bioavailability compared to standard ibuprofen.
The Ibuprofen Sodium market is projected to grow at a CAGR of 5.3% from 2025 to 2035, driven by its enhanced solubility and faster onset of action compared to traditional ibuprofen formulations.
The Icatibant Acetate market is projected to grow at a CAGR of 6.2% from 2025 to 2035, driven by its increasing use in the treatment of hereditary angioedema (HAE) and the growing awareness of this rare condition.
The Icosapent Ethyl market is projected to grow at a CAGR of 8.1% from 2025 to 2035, driven by its increasing use in managing cardiovascular diseases, particularly for reducing the risk of major adverse cardiovascular events (MACE) in patients with elevated triglyceride levels.
The Idarubicin Hydrochloride market is projected to grow at a CAGR of 6.2% from 2025 to 2035, driven by its continued use in the treatment of acute myeloid leukemia (AML) and other hematological malignancies.
The Ifosfamide market is projected to grow at a CAGR of 5.7% from 2025 to 2035, driven by its continued use in the treatment of various cancers, including testicular cancer, sarcomas, and lymphomas.
The Iguratimod market is projected to grow at a CAGR of 8.5% from 2025 to 2035, driven by its expanding use in the treatment of rheumatoid arthritis (RA) and other autoimmune diseases, particularly in the Asia-Pacific region.
The Ilaprazole market is projected to grow at a CAGR ranging from 5.6% to 11.6% between 2025 and 2035, driven by its expanding use in treating acid-related gastrointestinal disorders and its superior pharmacological profile compared to traditional proton pump inhibitors (PPIs).
The Ilaprazole Sodium market is projected to grow at a CAGR of 5.6% from 2025 to 2035, driven by its expanding use in treating acid-related gastrointestinal disorders and its superior pharmacological profile compared to traditional proton pump inhibitors (PPIs).
Search from 10,000 + API reports
How can we help you?
Reach out to discuss how our team can help your business achieve real results.
